317.87
0.99%
0.784
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$317.09
Aprire:
$318.42
Volume 24 ore:
30,420
Relative Volume:
0.08
Capitalizzazione di mercato:
$6.92B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-16.52
EPS:
-19.24
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+5.81%
1M Prestazione:
+53.31%
6M Prestazione:
+32.07%
1 anno Prestazione:
+69.95%
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
MDGL | 318.54 | 6.92B | 0 | -518.67M | -438.32M | -19.24 |
VRTX | 445.46 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 736.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.45 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-12-20 | Reiterato | Oppenheimer | Outperform |
2022-12-19 | Reiterato | H.C. Wainwright | Buy |
2022-12-19 | Reiterato | Piper Sandler | Overweight |
2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-10-07 | Iniziato | Jefferies | Buy |
2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2021-05-20 | Ripresa | Goldman | Buy |
2020-11-24 | Ripresa | Evercore ISI | Outperform |
2020-11-06 | Reiterato | H.C. Wainwright | Buy |
2020-07-31 | Iniziato | Piper Sandler | Overweight |
2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
2020-01-30 | Iniziato | Canaccord Genuity | Buy |
2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
2019-11-07 | Reiterato | H.C. Wainwright | Buy |
2019-06-25 | Iniziato | Stifel | Hold |
2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
2019-02-28 | Reiterato | H.C. Wainwright | Buy |
2019-02-22 | Iniziato | SVB Leerink | Outperform |
2019-01-23 | Iniziato | UBS | Neutral |
2018-12-14 | Iniziato | Wolfe Research | Outperform |
2018-12-12 | Iniziato | B. Riley FBR | Neutral |
2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
2018-09-04 | Iniziato | Citigroup | Buy |
2018-08-06 | Downgrade | Goldman | Buy → Neutral |
2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Connor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH - Scrip
(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com
(MDGL) Trading Report - Stock Traders Daily
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India
3 High Growth Tech Stocks Leading The US Market - Simply Wall St
B. Riley Has Bullish Estimate for MDGL FY2024 Earnings - MarketBeat
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy - Yahoo Finance
Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance
FY2028 Earnings Forecast for MDGL Issued By Leerink Partnrs - MarketBeat
Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN
MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN
Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily
Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Expectations By $2.02 EPS - MarketBeat
MDGL stock soars to 52-week high, reaching $299.99 - Investing.com
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):